background
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
routin
use
detect
viral
infect
brazil
mandatori
use
nucleic
acid
test
detect
hepat
c
viru
hcv
hepat
b
viru
human
immunodefici
viru
blood
bank
immunolog
window
use
intern
control
ic
necessari
differenti
true
neg
result
consequ
failur
step
nucleic
acid
test
object
aim
studi
construct
virusmodifi
particl
base
bacteriophag
use
ic
diagnosi
rna
virus
genom
clone
plasmid
gener
particl
produc
synthesi
rna
genom
rna
polymeras
particl
use
noncompetit
ic
assay
rna
viru
diagnost
addit
competit
control
hcv
diagnosi
develop
clone
mutat
hcv
sequenc
replicas
gene
produc
nonpropag
particl
util
particl
ic
evalu
onestep
format
multiplex
realtim
rtpcr
hcv
detect
find
demonstr
competit
noncompetit
ic
could
success
use
monitor
hcv
amplif
perform
includ
extract
revers
transcript
amplif
detect
step
without
compromis
detect
sampl
low
target
concentr
conclus
particl
gener
strategi
prove
use
ic
rna
viru
diagnosi
advantag
produc
low
cost
protocol
attract
featur
system
allow
construct
multicontrol
insert
sequenc
one
pathogen
increas
applic
diagnos
differ
rna
virus
polymeras
chain
reaction
pcr
use
extens
diagnost
tool
sinc
earli
use
pcr
revolutionis
diagnost
detect
microorgan
provid
rapid
specif
sensit
detect
microb
nucleic
acid
varieti
sampl
initi
falseposit
result
consequ
reaction
contamin
previous
gener
amplicon
main
concern
use
new
techniqu
measur
adopt
avoid
contamin
preamplifi
nucleic
acid
substanti
improv
achiev
introduct
realtim
pcr
realtim
pcr
close
tube
system
requir
postpcr
analysi
amplicon
still
consid
major
sourc
contamin
falseposit
result
execut
techniqu
addit
increas
focu
minimis
impact
falseneg
result
ie
assur
neg
result
truli
repres
absenc
pcr
diagnost
target
falseneg
result
occur
failur
one
test
step
nucleic
acid
extract
revers
transcript
reaction
pcr
set
amplif
first
measur
control
falseneg
result
base
addit
exogen
nucleic
acid
pcr
reaction
usual
plasmid
presenc
inhibitori
substanc
sampl
would
also
affect
amplif
exogen
materi
singl
multipl
intern
control
base
plasmid
construct
use
diagnost
sever
pathogen
et
al
dingl
et
al
hyma
et
al
maaroufi
et
al
type
control
howev
assess
amplif
step
case
viral
detect
necessari
control
prior
step
well
viral
particl
recoveri
plasma
viral
nucleic
acid
extract
therefor
strategi
develop
overcom
limit
initi
exogen
nucleic
acid
ad
nucleic
acid
extract
control
step
properli
assess
rel
loss
viral
particl
process
henc
ideal
control
protect
nucleic
acid
subject
exactli
step
viral
particl
addit
construct
protect
dna
rna
would
shield
nucleic
acid
degrad
nucleas
hydrolysi
longterm
storag
particular
import
one
need
use
rna
control
virus
pseudovir
particl
contain
kind
nucleic
acid
target
dna
rna
stabl
structur
design
undergo
simultan
step
target
pathogen
use
detect
assay
viral
target
cleland
et
al
garson
et
al
clanci
et
al
nonpathogen
virus
human
anim
prefer
pathogen
one
secur
reason
virus
easili
cheapli
produc
prefer
dreier
et
al
gerriet
et
al
ninov
et
al
two
class
exogen
intern
control
use
realtim
pcr
assay
competit
control
sequenc
specif
target
microorgan
allow
use
primer
pair
pcr
reaction
use
discriminatori
probe
noncompetit
control
use
detect
sequenc
unrel
microorgan
detect
competit
control
mimic
amplif
kinet
target
sequenc
howev
compet
target
sequenc
low
pathogen
load
besid
target
competit
control
must
construct
noncompetit
control
associ
sever
target
nevertheless
optimis
multiplex
pcr
two
differ
primer
pair
difficult
control
amplif
kinet
often
reflect
target
amplif
rosenstrau
et
al
hoorfar
et
al
sharma
et
al
benefit
disadvantag
strategi
care
analys
situat
choos
sever
report
publish
use
noncompetit
control
viral
detect
use
virus
bovin
diarrhea
viru
cleland
et
al
phocin
distemp
viru
clanci
et
al
murin
cytomegaloviru
garson
et
al
bacteriophag
dreier
et
al
rolf
et
al
gerriet
et
al
ninov
et
al
use
diagnosi
sever
dna
rna
virus
includ
hepat
c
viru
hcv
competit
control
develop
sever
virus
base
bacteriophag
lambda
et
al
berg
villanova
et
al
meng
et
al
pseudovir
particl
compris
viral
coat
protein
encapsul
nucleic
acid
specif
pathogen
develop
first
one
commerci
initi
call
armor
rna
base
coat
protein
paslosk
et
al
sever
work
report
use
kind
competit
control
walkerpeach
et
al
drosten
et
al
beld
et
al
cheng
et
al
zhao
et
al
wei
et
al
meng
et
al
felder
sharma
et
al
paper
describ
construct
virusmodifi
particl
base
bacteriophag
use
competit
intern
control
diagnosi
rna
virus
demonstr
applic
hcv
diagnosi
intern
control
allow
us
monitor
extract
revers
transcript
amplif
detect
step
particl
fulfil
characterist
ideal
intern
control
ie
produc
econom
protocol
infecti
anim
possess
sequenc
present
clinic
sampl
ribonucleas
resist
addit
propag
plasmid
replic
use
bacteri
dna
polymeras
less
prone
mutat
modif
viral
polymeras
gene
make
imposs
replic
infect
occur
protect
bacteri
stock
contamin
intern
control
construct
complementari
dna
rna
roch
mannheim
germani
synthes
use
primer
tabl
improm
ii
revers
transcriptas
promega
madison
wi
usa
primer
forward
revers
use
amplifi
bp
region
genom
use
gotaq
tm
dna
polymeras
promega
amplicon
purifi
agaros
gel
insert
pgemt
easi
vector
promega
gener
pgemt
plasmid
pgemt
subsequ
digest
noti
gener
fragment
bp
contain
genom
purifi
fill
use
klenow
fragment
dna
polymeras
new
england
biolab
hert
unit
kingdom
novagen
darmstadt
germani
digest
xbai
xhoi
enzym
new
england
biolab
liber
bp
fragment
polylink
region
purif
end
fill
klenow
fragment
dna
polymeras
dephosphoryl
shrimp
alkalin
phosphatas
amersham
pharmacia
biotech
piscataway
nj
usa
bp
region
origin
pgemt
excis
ligat
gener
stand
mutat
insert
sequenc
nt
deriv
hcv
subtyp
polyprotein
refer
sequenc
posit
clone
bamhi
site
purchas
genscript
piscataway
nj
usa
mhcv
sequenc
alter
base
compar
refer
sequenc
posit
fig
digest
bamhi
new
england
biolab
former
linearis
second
releas
mutat
hcv
sequenc
ligat
use
dna
ligas
invitrogen
carlsbad
ca
usa
linearis
vector
posit
genom
base
genbank
access
number
gener
region
plasmid
sequenc
use
intern
oligonucleotid
shown
plasmid
propag
conduct
transform
escherichia
coli
strain
pgemt
plasmid
miniprep
obtain
use
qiaprep
spin
miniprep
kit
hispe
plasmid
midi
kit
qiagen
germani
restrict
enzym
digest
fragment
purifi
agaros
gel
use
high
pure
pcr
product
purif
kit
roch
mannheim
germani
confirmatori
pcr
check
presenc
insert
orient
also
perform
shown
select
clone
sequenc
macrogen
inc
seoul
south
korea
intern
control
particl
product
transform
e
coli
transcript
genom
induc
addit
mm
h
bacteri
cell
pellet
centrifug
g
bacteriophag
particl
supernat
precipit
wv
polyethylen
glycol
h
centrifug
g
h
pellet
viral
particl
suspend
sm
medium
nacl
mm
mgso
trishcl
ph
gelatin
titer
particl
deriv
use
noncompetit
intern
control
determin
plaqu
form
unit
pfu
ml
plate
assay
e
coli
f
particl
deriv
use
competit
intern
control
quantifi
realtim
pcr
use
particl
refer
titer
express
pfuequival
pfueq
sampl
quantifi
hcv
rna
sampl
purchas
acrometrix
hcv
optiqu
hcv
rna
life
technolog
carlsbad
ca
usa
hcv
rna
linear
panel
seracar
life
scienc
milford
ct
usa
hiv
clinic
sampl
kindli
provid
lacenprbrazil
rna
extract
rna
hcv
clinic
sampl
bacteriophag
particl
extract
use
biopur
biometrix
curitiba
brazil
ibmp
extract
kit
ibmp
curitiba
brazil
ml
plasma
sampl
bacteriophag
solut
mixtur
two
accord
manufactur
instruct
automatis
solut
also
test
use
mdx
qiaamp
media
mdx
kit
ml
materi
qiagen
purifi
rna
elut
ml
appropri
buffer
onestep
realtim
pcr
intern
control
ic
amplifi
use
nm
primer
hcvfhcvr
nm
probe
mhcvp
multiplex
ic
done
nm
primer
hcvf
nm
nm
probe
hcvp
multiplex
reaction
ic
done
nm
primer
hcvf
nm
nm
probe
hcvp
mhcvp
multiplex
reaction
ic
amplifi
nm
primer
nm
hivf
hivr
primer
nm
probe
hivp
reaction
perform
ml
reaction
ml
rna
pcr
amplif
buffer
taq
dna
polymeras
dntp
ibmp
curitiba
brazil
u
revers
transcriptas
ibmp
curitiba
brazil
oligonucleotid
sequenc
shown
tabl
refer
duart
et
al
fig
modifi
hepat
c
viru
mhcv
sequenc
align
hcv
subtyp
refer
sequenc
number
indic
nucleotid
posit
refer
hcv
refer
sequenc
arrow
indic
first
last
probe
posit
underlin
probe
region
base
mhcv
sequenc
differ
hcv
genotyp
refer
sequenc
bamhi
site
gray
amplif
thermal
cycl
condit
began
initi
step
min
min
follow
cycl
min
abi
thermal
cycler
life
technolog
intern
control
construct
develop
competit
intern
control
use
assay
detect
nucleic
acid
hcv
base
bacteriophag
ic
could
also
use
noncompetit
control
rna
viru
detect
test
bacteriophag
genom
insert
plasmid
gener
construct
insert
mutat
hcv
sequenc
uniqu
bamhi
site
within
replicas
gene
genom
construct
confirm
sequenc
overview
strategi
shown
fig
could
gener
particl
synthesi
genom
rna
polymeras
gener
particl
whose
genom
harbor
nt
hcv
sequenc
middl
replicas
gene
consequ
nonfunct
enzym
produc
block
replic
genom
mutant
bacteriophag
particl
refer
ic
ic
respect
one
step
realtim
revers
transcriptasepcr
rtpcr
develop
optimis
control
rna
extract
tenfold
dilut
particl
stock
nucleic
acid
ic
amplifi
use
primer
probe
fig
mean
pcr
effici
rna
particl
amplifi
use
primer
hcvf
probe
mhcvp
fig
reaction
mean
effici
despit
amplif
sever
quantiti
carri
eight
log
test
linear
compris
six
log
ic
ic
could
quantifi
plate
assay
sinc
invad
replic
lyse
bacteri
cell
therefor
decid
quantifi
realtim
pcr
compar
curv
previous
quantifi
rna
extract
three
sampl
ic
subject
realtim
pcr
primer
probe
along
standard
curv
compris
serial
dilut
rna
titl
plate
assay
x
pfuml
ic
x
pfueq
noncompetit
intern
control
hcv
detect
reaction
util
particl
noncompetit
ic
evalu
onestep
format
multiplex
realtim
rtpcr
hcv
detect
use
set
primer
probe
amplif
genom
make
particl
use
ic
assay
rna
viru
hcv
primer
design
amplifi
region
posit
genbank
refer
sequenc
conserv
among
differ
genotyp
duart
et
al
particl
test
noncompetit
intern
control
primer
pair
probe
use
singleplex
reaction
plu
primer
probe
detect
hcv
tabl
sampl
hcv
rna
linear
panel
dilut
x
uiml
spike
ml
ic
pfu
rna
hcv
ic
extract
amplifi
multiplex
realtim
pcr
fig
hcv
amplif
detect
c
wherea
c
averag
experi
indic
ic
amplif
reproduc
neglig
interfer
hcv
detect
independ
amount
ic
therefor
opt
use
pfu
ic
subsequ
test
competit
ic
hcv
detect
reaction
evalu
competit
ic
onestep
realtim
pcr
hcv
detect
hcv
region
target
hcv
detect
insert
mutat
base
relat
wildtyp
wt
sequenc
multiplex
pcr
requir
one
hcv
primer
pair
two
probe
discrimin
wt
mutat
sequenc
probe
hcv
ic
design
posit
refer
sequenc
tabl
x
uiml
use
multiplex
reaction
pfueq
ic
fig
quantiti
ic
test
suitabl
amplif
curv
c
despit
greater
variabl
pfueq
amplif
multiplex
reaction
differ
amount
competit
ic
affect
amplif
hcv
subsequ
test
ad
pfueq
ic
sampl
fig
show
hcv
c
valu
multiplex
reaction
close
regardless
whether
ic
competit
noncompetit
evalu
multiplex
hcvic
realtim
pcr
extend
ad
ic
pfu
ic
pfueq
hcv
panel
sampl
uiml
ic
detect
sampl
mean
c
mean
c
ic
x
x
hcv
amplif
curv
similar
among
reaction
use
competit
noncompetit
ic
valu
report
tabl
ii
plot
amplif
imag
shown
supplementari
data
figur
noncompetit
ic
human
immunodefici
hiv
detect
reaction
addit
particl
evalu
noncompetit
ic
onestep
format
multiplex
realtim
pcr
hiv
detect
demonstr
control
use
assay
rna
viru
primer
probe
amplifi
ic
multiplex
reaction
one
hiv
clinic
sampl
viral
load
log
spike
ml
ic
pfu
rna
hiv
ic
extract
amplifi
multiplex
realtim
pcr
fig
hiv
amplif
detect
c
c
result
show
pfu
disturb
hiv
amplif
pfu
appear
optimum
amount
control
reaction
result
c
hiv
equal
test
without
control
aim
present
work
construct
ic
assess
differ
step
rna
viru
detect
test
base
realtim
pcr
rna
extract
amplif
reaction
chosen
suitabl
viru
ad
sampl
rna
viru
encapsul
genom
protect
rnase
easili
handl
basic
molecular
biolog
techniqu
nonpathogen
human
requir
extra
care
regard
biolog
safeti
addit
necessari
work
e
coli
human
blood
sampl
hcv
rna
viru
chosen
model
construct
valid
control
bacteriophag
belong
levivirida
famili
nt
singl
strand
rna
genom
encod
four
protein
maturas
involv
infect
e
coli
pilu
ii
coat
protein
selfassembl
icosaedr
shape
form
monom
iii
lysi
protein
involv
bacteri
cell
lysi
iv
replicas
protein
rnadepend
rna
polymeras
rdrp
fier
et
al
construct
ic
whole
genom
clone
vector
novagen
gener
first
version
ic
plasmid
transcrib
transcript
via
rna
polymeras
capabl
produc
particl
particl
use
noncompetit
ic
pcr
reaction
detect
rna
virus
use
oligonucleotid
set
specif
genom
transform
noncompetit
ic
competit
ic
rna
viru
reaction
modifi
sequenc
elect
viru
must
insert
genom
modif
sequenc
necessari
allow
differenti
probe
discrimin
pathogen
sequenc
ic
plate
well
thu
second
version
ic
competit
ic
gener
insert
modifi
hcv
sequenc
middl
replicas
gene
insert
sequenc
ident
wildtyp
sequenc
length
gc
content
henc
amplif
effici
hcv
control
factor
interf
one
target
amplif
would
interfer
rate
introduct
sequenc
replicas
gene
produc
nonfunct
rna
polymeras
meant
transform
bacteria
produc
viral
particl
via
plasmid
polymeras
encod
bacteri
genom
particl
chanc
infect
polymeras
express
bacteri
stock
could
replic
fortuit
infect
polymeraseexpress
strain
would
gener
phage
particl
without
induct
nucleic
acid
test
nat
hcv
hiv
develop
fiocruzbrazil
use
brazilian
blood
bank
patent
number
chose
test
perform
ic
competit
noncompetit
use
primer
probe
use
test
applic
competit
noncompetit
ic
hcv
detect
demonstr
work
also
show
applic
noncompetit
control
detect
realtim
pcr
although
reaction
optimis
establish
ideal
concentr
ic
interfer
amplif
done
hcv
show
result
onestep
realtim
rtpcr
realtim
pcr
hcv
use
ic
also
success
reproduc
twostep
format
data
shown
previou
work
demonstr
use
wildtyp
particl
ic
sever
pathogen
rolf
et
al
dreier
cowork
use
control
hcv
diagnosi
dreier
et
al
studi
howev
produc
via
biolog
cycl
infect
lysi
bacteria
produc
particl
plasmid
regul
fashion
diminish
step
could
caus
contamin
laboratorystor
bacteri
stock
villanova
et
al
anoth
advantag
use
plasmid
contain
sequenc
replic
plasmid
via
bacteri
dna
polymeras
gener
fewer
mutat
replic
rna
polymeras
replicas
fier
et
al
avoid
risk
contamin
laboratori
bacteri
stock
nongener
mutat
replic
rdrp
advantag
pseudovir
particl
use
competit
ic
satisfi
requir
paslosk
et
al
one
concern
possibl
ic
interfer
detect
limit
test
fiocruz
test
sensit
iuml
hcv
albertoni
et
al
report
limit
detect
onestep
rtpcr
hcv
detect
iuml
wendel
et
al
report
detect
limit
iuml
inhous
hcv
realtim
rtpcr
test
two
work
use
ic
villanova
et
al
develop
competit
control
hcv
diagnost
base
anoth
viru
obtain
detect
limit
iu
ml
work
dreier
et
al
perform
hcv
test
ic
abl
detect
pfu
ic
use
pfu
ic
hiv
c
use
pfu
hiv
c
use
pfu
hiv
c
b
hiv
singleplex
realtim
revers
transcriptas
polymeras
chain
reaction
rtpcr
reaction
horizont
line
correspond
measur
fluoresc
iuml
although
duplex
reaction
decreas
hcv
fluoresc
observ
compar
singleplex
reaction
iuml
system
abl
detect
iuml
valu
compar
fiocruz
test
thu
addit
ic
alreadi
optimis
reaction
possibl
without
compromis
origin
perform
step
optimis
pseudoviru
commerci
control
also
base
particl
also
avail
sever
format
sever
pathogen
includ
hcv
cost
howev
hamper
broad
use
develop
countri
ic
approach
use
countri
sinc
develop
inhous
sequenc
interest
insert
bamhi
site
framework
plasmid
contain
sequenc
provid
versatil
creat
noncompetit
competit
ic
attract
featur
system
allow
construct
multicontrol
insert
sequenc
one
pathogen
increas
applic
ic
diagnos
differ
rna
virus
work
construct
ic
rna
viru
diagnosi
realtim
rtpcr
use
hcv
model
despit
need
extend
evalu
use
larger
characteris
panel
clinic
sampl
demonstr
competit
noncompetit
ic
success
assess
hcv
amplif
perform
without
compromis
detect
low
titer
sampl
